Perspective Therapeutics, Inc. (NYSE:CATX) Receives Average Recommendation of “Moderate Buy” from Brokerages

Perspective Therapeutics, Inc. (NYSE:CATX) has been given an average recommendation of “Moderate Buy” by the nine analysts that are currently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a hold rating and eight have given a buy rating to the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $15.14.

Several research firms have weighed in on CATX. Bank of America cut Perspective Therapeutics from a “buy” rating to a “neutral” rating and reduced their price target for the stock from $24.00 to $5.00 in a research report on Monday, November 25th. Wedbush reissued an “outperform” rating and issued a $11.00 price target (down from $20.00) on shares of Perspective Therapeutics in a report on Thursday, November 21st. Oppenheimer decreased their price target on shares of Perspective Therapeutics from $22.00 to $16.00 and set an “outperform” rating on the stock in a research note on Friday, November 22nd. Truist Financial started coverage on Perspective Therapeutics in a research note on Wednesday, September 25th. They issued a “buy” rating and a $21.00 price target on the stock. Finally, UBS Group initiated coverage on Perspective Therapeutics in a research note on Thursday, October 24th. They set a “buy” rating and a $20.00 price objective for the company.

Perspective Therapeutics Price Performance

CATX opened at $3.25 on Wednesday. Perspective Therapeutics has a fifty-two week low of $2.70 and a fifty-two week high of $19.05. The business has a fifty day simple moving average of $7.61 and a 200-day simple moving average of $11.03.

Perspective Therapeutics (NYSE:CATX) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.21) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.21). Perspective Therapeutics had a negative return on equity of 27.40% and a negative net margin of 4,096.66%. The firm had revenue of $0.37 million during the quarter. As a group, equities analysts expect that Perspective Therapeutics will post -0.88 EPS for the current year.

Insiders Place Their Bets

In other news, Director Heidi Henson acquired 25,975 shares of the stock in a transaction that occurred on Wednesday, December 4th. The stock was acquired at an average price of $3.85 per share, for a total transaction of $100,003.75. Following the transaction, the director now directly owns 25,975 shares in the company, valued at approximately $100,003.75. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Johan M. Spoor acquired 8,000 shares of the business’s stock in a transaction dated Wednesday, December 4th. The shares were acquired at an average price of $3.77 per share, for a total transaction of $30,160.00. Following the acquisition, the chief executive officer now directly owns 36,257 shares in the company, valued at $136,688.89. This represents a 28.31 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have purchased a total of 67,570 shares of company stock valued at $256,789 in the last 90 days. 3.52% of the stock is currently owned by insiders.

Institutional Trading of Perspective Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Charles Schwab Investment Management Inc. increased its stake in shares of Perspective Therapeutics by 221.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 433,522 shares of the company’s stock worth $5,788,000 after purchasing an additional 298,778 shares during the last quarter. WealthPlan Investment Management LLC bought a new position in shares of Perspective Therapeutics in the third quarter valued at about $4,530,000. Hills Bank & Trust Co acquired a new position in shares of Perspective Therapeutics in the third quarter valued at approximately $13,722,000. Janus Henderson Group PLC boosted its position in shares of Perspective Therapeutics by 8.0% in the third quarter. Janus Henderson Group PLC now owns 4,799,352 shares of the company’s stock valued at $64,014,000 after acquiring an additional 355,685 shares during the period. Finally, FMR LLC grew its position in Perspective Therapeutics by 3,994.9% during the third quarter. FMR LLC now owns 5,504,822 shares of the company’s stock worth $73,489,000 after buying an additional 5,370,392 shares in the last quarter. 54.66% of the stock is currently owned by institutional investors and hedge funds.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.